(Total Views: 159)
Posted On: 02/06/2017 2:54:34 PM
Post# of 53553
$ENTB Zander Therapeutics is a wholly owned subsidiary of Entest BioMedical Inc. (ENTB), a publicly traded biotechnology company focused on veterinary medicine. The Company seeks to develop small molecule and immune stimulating therapies for veterinary application. Currently, the Company's major interest is in developing small molecule therapies for treating cancer and autoimmune diseases in animals, which include arthritis.
Zander Therapeutics Inc. is the exclusive licensee for veterinary applications of Regen BioPharma Inc. (RGBP) (RGBPP) intellectual property and technology relating to NR2F6. NR2F6 is a molecular switch known as a "orphan nuclear receptor", which controls genes associated with the immune response. Zander Therapeutics is solely focused on veterinary applications.
David Koos serves as Chairman and Chief Executive officer of Regen BioPharma, Inc. (RGBP), Entest BioMedical Inc. (ENTB) and Zander Therapeutics Inc. (wholly owned by Entest BioMedical Inc.).
http://finance.yahoo.com/news/entest-biomedic...NlYwNzYw--
Zander Therapeutics Inc. is the exclusive licensee for veterinary applications of Regen BioPharma Inc. (RGBP) (RGBPP) intellectual property and technology relating to NR2F6. NR2F6 is a molecular switch known as a "orphan nuclear receptor", which controls genes associated with the immune response. Zander Therapeutics is solely focused on veterinary applications.
David Koos serves as Chairman and Chief Executive officer of Regen BioPharma, Inc. (RGBP), Entest BioMedical Inc. (ENTB) and Zander Therapeutics Inc. (wholly owned by Entest BioMedical Inc.).
http://finance.yahoo.com/news/entest-biomedic...NlYwNzYw--
(0)
(0)
Consider all my posts my opinion and not advice to buy or sell anything. I post on stocks I own or am considering owning. Do your own DD!
